MESA LABORATORIES INC /CO/ - Quarter Report: 2018 September (Form 10-Q)

 

 

Table of Contents

---

---

 

United States

Securities and Exchange Commission

Washington, D.C. 20549

 

---

 

FORM 10-Q

 

☒     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

or

 

☐     TRANSITION REPORT PURSUANT TOSECTION 13 OR 15 (d) OF THE SECURITES EXCHANGE ACT OF 1934

 

For the transition period from ___ to ___

 

Commission File No: 0-11740

 

---

 

MESA LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

 

Colorado		84-0872291
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification number)
12100 West Sixth Avenue
Lakewood, Colorado		80228
(Address of principal executive offices)		(Zip Code)

 

Registrant’s telephone number, including area code: (303) 987-8000

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934, during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒   No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒     No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

Accelerated filer ☒

Non-accelerated filer ☐

Smaller reporting company ☒

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐     No ☒

 

Indicate the number of shares outstanding of each of the Issuer’s classes of common stock, as of the latest practicable date:

 

There were 3,852,835 shares of the Issuer’s common stock, no par value, outstanding as of October 26, 2018.

 

---

 

 

Table of Contents

 

PART I. FINANCIAL INFORMATION	1
ITEM 1. FINANCIAL STATEMENTS	1
Condensed Consolidated Balance Sheets	1
Condensed Consolidated Statements of Income	2
Condensed Consolidated Statements of Comprehensive Income	3
Condensed Consolidated Statements of Cash Flows	4
Notes to Condensed Consolidated Financial Statements	5
ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	15
ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	21
ITEM 4.  CONTROLS AND PROCEDURES	21
PART II. OTHER INFORMATION	21
ITEM 1.  LEGAL PROCEEDINGS	21
ITEM 1A.  RISK FACTORS	22
ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	22
ITEM 6.  EXHIBITS	23
SIGNATURES	24
EXHIBIT 31.1 CERTIFICATIONS PURSUANT TO RULE 13A-14(A)
EXHIBIT 31.2 CERTIFICATIONS PURSUANT TO RULE 13A-14(A)
EXHIBIT 32.1 CERTIFICATIONS PURSUANT TO RULE 13A-14(B) AND 18 U.S.C SECTION 1350
EXHIBIT 32.2 CERTIFICATIONS PURSUANT TO RULE 13A-14(B) AND 18 U.S.C SECTION 1350

 

---

 

		September 30,
		2018				March 31,
		(unaudited)				2018
ASSETS
Current assets:
Cash and cash equivalents		$	5,625			$	5,469
Accounts receivable, less allowances of $128 and $179, respectively			13,242				14,302
Inventories, net			8,336				9,228
Prepaid income taxes			4,165				273
Prepaid expenses and other			2,223				782
Assets held for sale			--				1,934
Total current assets			33,591				31,988
Property, plant and equipment, net			23,235				23,593
Deferred taxes			120				127
Intangibles, net			38,260				42,850
Goodwill			65,082				65,543
Total assets		$	160,288			$	164,101
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable		$	2,295			$	2,380
Accrued salaries and payroll taxes			4,607				4,284
Current portion of long-term debt			1,875				1,625
Unearned revenues			3,744				3,921
Current portion of contingent consideration			46				709
Income taxes payable			--				1,008
Estimated legal liability			3,300				--
Other accrued expenses			3,665				3,363
Total current liabilities			19,532				17,290
Deferred income taxes			2,532				2,621
Long-term debt, net of debt issuance costs and current portion			31,188				44,635
Other long-term liabilities			133				194
Total liabilities			53,385				64,740
Stockholders’ equity:
Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 3,852,747 and 3,801,439 shares, respectively			35,421				30,516
Retained earnings			72,279				68,281
Accumulated other comprehensive (loss) income			(797	)			564
Total stockholders’ equity			106,903				99,361
Total liabilities and stockholders’ equity		$	160,288			$	164,101

---

 

		Three Months Ended September 30,								Six Months Ended September 30,
		2018				2017				2018				2017
Revenues		$	24,865			$	22,954			$	50,007			$	45,627
Cost of revenues			10,288				9,721				20,339				19,723
Gross profit			14,577				13,233				29,668				25,904
Operating expenses:
Selling			1,804				2,288				3,694				4,967
General and administrative			7,493				6,412				15,093				13,269
Research and development			842				885				1,679				2,038
Estimated legal settlement			3,300				--				3,300				--
Total operating expenses			13,439				9,585				23,766				20,274
Operating income			1,138				3,648				5,902				5,630
Other (income) expense, net			(168	)			542				196				1,221
Earnings before income taxes			1,306				3,106				5,706				4,409
Income tax expense			312				753				482				539
Net income		$	994			$	2,353			$	5,224			$	3,870
Earnings per share:
Basic		$	0.26			$	0.63			$	1.36			$	1.03
Diluted			0.25				0.60				1.30				0.98
Weighted-average common shares outstanding:
Basic			3,850				3,764				3,833				3,754
Diluted			4,046				3,935				4,029				3,934

---

 

		Three Months Ended September 30,								Six Months Ended September 30,
		2018				2017				2018				2017
Net income		$	994			$	2,353			$	5,224			$	3,870
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments			(49	)			948				(1,361	)			1,699
Comprehensive income		$	945			$	3,301			$	3,863			$	5,569

---

 

		Six Months Ended September 30,
		2018				2017
Cash flows from operating activities:
Net income		$	5,224			$	3,870
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			4,889				4,531
Stock-based compensation			1,729				985
Gain on disposition of assets			(288	)			(116	)
Deferred taxes			--				144
Foreign currency adjustments			--				(533	)
Adjustment to contingent consideration			(33	)			300
Other			111				55
Cash provided by changes in operating assets and liabilities:			--
Accounts receivable, net			643				2,132
Inventories, net			1,022				960
Prepaid expenses and other current assets			(1,301	)			(2,241	)
Accounts payable			(70	)			(132	)
Accrued liabilities and taxes payable			(866	)			(1,819	)
Unearned revenues			(177	)			(312	)
Contingent consideration			(683	)			(456	)
Net cash provided by operating activities			10,200				7,368
Cash flows from investing activities:
Acquisitions			--				(62	)
Proceeds from sale of assets			2,222				1,133
Purchases of property, plant and equipment			(849	)			(2,012	)
Net cash provided by (used in) investing activities			1,373				(941	)
Cash flows from financing activities:
Proceeds from the issuance of debt			--				4,000
Payments on debt			(13,250	)			(7,000	)
Dividends			(1,226	)			(1,201	)
Proceeds from the exercise of stock options			3,176				2,064
Net cash used in financing activities			(11,300	)			(2,137	)
Effect of exchange rate changes on cash and cash equivalents			(117	)			158
Net increase in cash and cash equivalents			156				4,448
Cash and cash equivalents at the beginning of the period			5,469				5,820
Cash and cash equivalents at the end of the period		$	5,625			$	10,268
Cash paid for:
Income taxes paid		$	5,310			$	2,446
Interest paid			938				1,007

---

 

Note 1. Description of Business and Summary of Significant Accounting Policies

 

Description of Business

 

In this quarterly report on Form 10-Q, Mesa Laboratories, Inc., a Colorado corporation, together with its subsidiaries is collectively referred to as “we,” “us,” “our,” the “Company” or “Mesa.”

 

We pursue a strategy of focusing primarily on quality control products and services which are sold into niche markets that are driven by regulatory requirements. We prefer markets in which we can establish a strong presence and achieve high gross margins. We are organized into four divisions across nine physical locations. Our Sterilization and Disinfection Control Division manufactures and sells biological, cleaning, and chemical indicators. Biological, cleaning, and chemical indicators are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. The division also provides testing and laboratory services, mainly to the dental industry. Our Instruments Division designs, manufactures, and markets quality control instruments and disposable products utilized in the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, and environmental air sampling industries. Our Cold Chain Monitoring Division designs, develops, and markets systems which are used to monitor various environmental parameters such as temperature, humidity, and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies, and laboratory environments. Our Cold Chain Packaging Division provides packaging development consulting services and thermal packaging products such as coolers, boxes, insulation materials, and phase-change products to control temperature during the customer’s transport of their own products.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, such unaudited information includes all adjustments, consisting of normal recurring adjustments necessary for a fair presentation of our financial position and results of operations. The results of operations for the interim periods are not necessarily indicative of results that may be achieved for the entire year. The financial statements and related notes do not include all information and footnotes required by U.S. GAAP for annual reports. This quarterly report should be read in conjunction with the consolidated financial statements included in our annual report on Form 10-K for the year ended March 31, 2018.

 

Recently Issued Accounting Pronouncements

 

In August 2018, the SEC issued Release No. 33-10532 that amends and clarifies certain financial reporting requirements. The principal change to our financial reporting will be the inclusion of the annual disclosure requirement of changes in stockholders’ equity in Rule 3-04 of Regulation S-X to interim periods. We will adopt this new rule beginning with our financial reporting for the quarter ended December 31, 2018. Upon adoption, we will include our Consolidated Statements of Stockholders' Equity with each quarterly filing on Form 10-Q.

 

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842). The pronouncement requires lessees to recognize a liability for lease obligations, which represents the discounted obligation to make future minimum lease payments, and a corresponding right-of-use asset on the balance sheet for all leases with terms greater than 12 months. The guidance also requires qualitative and quantitative disclosures designed to present financial statement users with the ability to assess the amount, timing, and uncertainty of cash flows arising from leases. We have initiated our plan for the adoption and implementation of this new accounting standard, including assessing our lease arrangements, evaluating practical expedients, and making necessary changes to our accounting policies, processes, and internal controls over financial reporting. We expect to adopt the standard using the optional transition method, which will allow us to apply the standard as of the effective date, therefore we will not apply changes to comparative periods presented in our financial statements. We are still assessing the expected impact of the standard on our consolidated balance sheets, but it will not significantly impact our consolidated statements of income and cash flows.

 

 

Recently Adopted Accounting Pronouncements

 

During the three months ended September 30, 2018, we elected to early-adopt ASU 2018-15 Intangibles – Goodwill and Other Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”) on a prospective basis. ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs of other internal-use software arrangements. Accordingly, we capitalized $144 of costs incurred during the three months ended September 30, 2018 to implement a hosted enterprise resource planning system to our European subsidiaries. The related asset is held in prepaid expenses and other on the condensed consolidated balance sheets, and we began amortizing the expense to general and administrative costs on our condensed consolidated statements of income on a straight-line basis over the contractual term of the arrangement.

 

Effective April 1, 2018, we adopted ASU 2014-09 Revenue from Contracts with Customers (Topic 606) and all related amendments (referred to collectively hereinafter as “ASU 606”) on a modified retrospective basis. ASU 606 requires an entity to recognize revenue for the transfer of goods or services equal to the amount it expects to be entitled to receive for the goods and services. The adoption did not have a material impact on our condensed consolidated balance sheets, statements of income, or cash flows. The primary impact of adoption was the enhancement of disclosures to provide additional clarity regarding how revenue is earned and recognized, and to show revenues at a more disaggregated level, included in Note 2. “Revenue Recognition.”

 

In March 2018, the FASB issued ASU 2018-05, Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118. The amendments in this update provide guidance on when to record and disclose provisional amounts for certain income tax effects of the Tax Cuts and Jobs Act ("TCJA"). The amendments also require any provisional amounts or subsequent adjustments to be included in net income from continuing operations. Additionally, this ASU discusses required disclosures that an entity must make with regard to the TCJA. This ASU is effective immediately as new information is available to adjust provisional amounts that were previously recorded. We have adopted this standard and will continue to evaluate indicators that may give rise to a change in our tax provision as a result of the TCJA. Refer to Note 7. “Income Taxes” for additional information on the TCJA.

 

Note 2. Revenue Recognition

 

We design, manufacture, market, sell, and maintain quality control instruments, consumables, and services driven primarily by the regulatory requirements of niche markets. Our consumables, such as biological indicator test strips and packaging materials, are typically used on a standalone basis; however, some, such as calibration solutions, are also critical to the ongoing use of our instruments. Instruments sales, such as medical meters, wireless sensors, and data loggers are generally driven by our acquisition of new customers, growth of existing customers, or customer replacement of existing equipment. We generally generate service revenues from three categories: 1) discrete installation of our hardware, 2) discrete but recurring calibration and maintenance of our hardware or 3) contracted and recurring testing and maintenance services. We evaluate our revenues internally both by product line as well as by timing of revenue generation and nature of goods and services provided. Typically, discrete revenue is recognized at the shipping point or upon completion of the service, while contracted revenue is recognized over a period of time reflective of the performance obligation period in the applicable contract.

 

Substantially all of our revenues and related receivables are generated from contracts with customers that are 12 months or less in duration. For both discrete and contracted revenue, evidence of an arrangement is typically in the form of a formal contract and/or purchase order. Prices are fixed at the time of the order and no price protections or variables are offered. Collectability is reasonably assured through our customer credit and review process, and payment is typically due within 60 days or less. Revenue is recognized when performance obligations under the terms of the contracts with our customers are satisfied. We elected to adopt the practical expedient that allows us to expense commission costs as incurred.

 

Our performance obligations related to the sale of instruments and consumables generally consist of the promise to sell tangible goods to distributors or end users. Ownership of these goods is typically transferred at time of shipment, at which point we have satisfied our performance obligation and we recognize revenue.

 

Our performance obligations related to services may include testing, installation, and/or maintenance of our products, either on-site at our customers’ facilities or in our own calibration laboratories. Performance obligations arise from service contracts when discrete services are contracted in advance and performed at a future time, often at the time of the customer’s choosing. In this case, the performance obligation is satisfied, and revenue is recognized, upon the customer’s acceptance of the completion of the specified work. Alternately, service revenue may be recognized for contracted services or maintenance provided continually over a period of time, and our performance obligations are satisfied by completing any service that is contractually required, if applicable, or simply by the passage of time if no services are required or requested. For contracted services, revenue is recognized on a straight-line basis over the life of the service contract, which is a faithful depiction of these annual service contracts, which may or may not be invoked.

 

 

The following tables present disaggregated revenues for the three and six months ended September 30, 2018 and September 30, 2017, respectively:

 

 

 

 

 

 

 

 

Contract Balances

 

Our contracts have varying payment terms and conditions. Some customers prepay for services, resulting in unearned revenues or customer deposits, called contract liabilities, which are included within other accrued expenses and unearned revenues in the accompanying condensed consolidated balance sheets. Contract assets would exist when sales are recorded (i.e. the control of the goods or services has been transferred to the customer), but customer payment is contingent on a future event besides the passage of time (such as satisfaction of additional performance obligations). We do not have any contract assets. Unbilled receivables, which are not classified as contract assets, represent arrangements in which sales have been recorded prior to billing and right to payment is unconditional.

 

A summary of contract liabilities is as follows:

 

 

 

Note 3. Inventories

 

Inventories consist of the following:

 

 

 

Note 4. Facility Relocation

 

In August 2016, we announced that we planned to shut down both our Omaha and Traverse City manufacturing facilities and relocate those operations to the new Bozeman building. The move of those two facilities, along with the current Bozeman operations, began in March 2017 and was completed as of June 30, 2018. The total cost of the relocation was $1,584 (which is comprised primarily of facility moving expenses, retention bonuses for existing personnel and payroll costs for duplicative personnel during the transition period) and these costs pertain to the Sterilization and Disinfection Control Division.

 

 

Facility relocation amounts accrued and paid for the six months ended September 30, 2018 are as follows:

 

 

We completed the sale of our old Bozeman facility during the period ended September 30, 2018, for $2,222 (net of commissions) resulting in a gain of $288, which is recorded in other (income) expense, net on our condensed consolidated statements of income.

 

Note 5. Long-Term Debt

 

Long-term debt consists of the following:

 

 

On March 1, 2017, we entered into a five-year agreement (the “Credit Facility”) for an $80,000 revolving line of credit (“Line of Credit”), a $20,000 term loan (“Term Loan”) and up to $2,500 of letters of credit with a banking syndicate of four banks. In addition, the Credit Facility provides a post-closing accordion feature which allows for the Company to request to increase the Line of Credit or Term Loan up to an additional $100,000.

 

Line of Credit and Term Loan indebtedness bears interest at either: (1) LIBOR, as defined in the agreement, plus an applicable margin ranging from 1.50% to 2.50%; or (2) the alternate base rate (“ABR”), which is the greater of JPMorgan’s prime rate or the federal funds effective rate or the overnight bank funding rate plus 0.5%. We elect the interest rate with each borrowing under the line of credit. In addition, there is an unused line fee of 0.15% to 0.35%. Letter of credit fees are based on the applicable LIBOR rate.

 

The Credit Facility is secured by all of our assets and requires us to maintain a ratio of funded debt to our trailing four quarters of EBIDTA (the “Leverage Ratio”), as defined in the agreement, of less than 3.0 to 1.0, provided that, we may once during the term of the Credit Facility, in connection with a Permitted Acquisition for which the aggregate consideration paid or to be paid in respect thereof equals or exceeds $20,000, elect to increase the maximum Leverage Ratio permitted hereunder to (i) 3.50 to 1.00 for a period of four consecutive fiscal quarters commencing with the fiscal quarter in which such Permitted Acquisition occurs (the “Initial Holiday Period”) and (ii) 3.25 to 1.00 for the period of four consecutive fiscal quarters immediately following the Initial Holiday Period. The Credit Facility also requires us to maintain a minimum fixed charge coverage ratio of less than 1.25 to 1.0. We were in compliance with all debt covenants as of September 30, 2018.

 

As of September 30, 2018, future contractual maturities of debt are as follows:

 

 

 

Note 6. Stock-Based Compensation

 

During the six months ended September 30, 2018, we granted restricted stock units (“RSUs”) on 15,919 shares of our common stock to eligible employees. The weighted average grant date fair value of the RSUs was $151.54 per share. The RSUs generally vest in equal installments on the anniversary of the grant date over a period of five years. During the six months ended September 30, 2018, 1,720 RSUs vested, and 185 RSUs were forfeited or cancelled.

 

 

During the six months ended September 30, 2018, we awarded 11,385 performance share units (“PSUs”) that are subject to both service and performance conditions to eligible employees. The PSUs had a grant date fair value of $192.99 per share and vest both based on our achievement of specific performance criteria for the three-year period from April 1, 2018 through March 31, 2021, as well as continued service through June 15, 2021. The quantity of shares that will be issued upon vesting will range from 0 percent to 400 percent of the targeted number of shares; if the defined minimum targets are not met, then no shares will vest.

 

During the six months ended September 30, 2018, we granted non-qualified stock options (“NQSOs”) on 24,940 shares of common stock to eligible employees. The weighted-average grant date fair value of the NQSOs was $53.56 per share with a weighted average exercise price of $143.36 per share based on the closing price of the common stock on the date of grant. The NQSOs generally vest in equal installments on the anniversary of the grant date over a period of five years.

 

Amounts recognized in the condensed consolidated financial statements related to stock-based compensation are as follows:

 

 

Stock-based compensation expense is included in cost of revenues, selling, general and administrative, and research and development expense in the accompanying condensed consolidated statements of income.

 

The following is a summary of stock option and non-vested stock award activity for the six months ended September 30, 2018 (shares in thousands):

 

 

We issue shares in connection with stock-based compensation pursuant to the Mesa Laboratories, Inc. 2014 Equity Plan (the “2014 Equity Plan”). For the purposes of counting the shares remaining as available under the 2014 Incentive Plan, each share issuable pursuant to outstanding full value awards, such as RSUs and PSUs, counts as five shares issued, whereas each share underlying a stock option counts as one share issued. Under the 2014 Equity Plan, 1,100,000 shares of common stock have been authorized and reserved for eligible participants, of which 595,729 shares were available for future grants as of September 30, 2018.

 

Note 7. Income Taxes

 

For interim income tax reporting, we estimate our annual effective tax rate and apply this effective tax rate to our year-to-date pre-tax income. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. Additionally, the tax effects of significant unusual or infrequently occurring items are recognized as discrete items in the interim period in which the events occur. The impact of changes in tax laws or rates on deferred tax amounts, excess benefits from stock-based compensation, impairments of non-deductible goodwill, and changes in tax reserves resulting from the finalization of tax audits or reviews are examples of significant unusual or infrequently occurring items that are recognized as discrete items in the interim period in which the event occurs. There is a potential for volatility of the effective tax rate due to several factors, including excess benefits from stock-based compensation, changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, settlement with taxing authorities, and foreign currency fluctuations.

 

 

On December 22, 2017, the Tax Cuts and Jobs Act ("TCJA") was enacted in the U.S., making significant changes to U.S. tax law. The TCJA reduces the U.S. federal corporate income tax rate from 34 percent to 21 percent for tax years beginning after December 31, 2017, requires companies to pay a one-time transition tax on certain un-remitted earnings of foreign subsidiaries that were previously tax deferred, generally eliminates U.S. federal income tax on dividends from foreign subsidiaries, creates new taxes on certain foreign-sourced earnings, repeals the Section 199 deduction, and imposes limitations on the deductibility of executive compensation under Section 162(m).

 

Shortly thereafter, the Securities and Exchange Commission staff issued SAB 118, which provides guidance on accounting for the tax effects of the TCJA for which the accounting under ASC 740 is incomplete. To the extent that a company's accounting for certain income tax effects of the TCJA is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before enactment of the TCJA. The Company is required to complete its tax accounting for the TCJA within a one-year period when it has obtained, prepared, and analyzed the information to complete the income tax accounting.

 

Accordingly, as of September 30, 2018, we have not completed our accounting for the tax effects of the TCJA. During our fiscal year ended March 31, 2018, we made a reasonable estimate of the one-time transition tax and recognized a provisional tax liability of $220. We also re-measured the applicable deferred tax assets and liabilities based on the rates at which they are expected to reverse. However, we are still analyzing certain aspects of the TCJA and refining our calculations, which could potentially affect the measurement of these balances or potentially give rise to new deferred tax amounts. The provisional amount recorded related to the re-measurement of our deferred tax balance was a benefit of $279. Overall, the TCJA resulted in a net tax benefit of $59. Such amount was recorded as a discrete tax benefit and was included as a component of income tax expense for the year ended March 31, 2018.

 

Our effective income tax rate was 23.9 percent and 24.2 percent for the three months ended September 30, 2018 and September 30, 2017, respectively, and 8.4 percent and 12.2 percent for the six months ended September 30, 2018 and September 30, 2017, respectively. The effective tax rate for the six months ended September 30, 2018 differed from the statutory federal rate of 21 percent primarily due to the impact of share-based payment awards for employees, state income taxes, foreign derived intangible income deduction, and the foreign rate differential.

 

Since we are subject to audit by various taxing authorities, it is reasonably possible that the amount of unrecognized tax benefits will change during the next 12 months. However, we do not expect the change, if any, to have a material effect on our financial condition or results of operations within the next 12 months.

 

Note 8. Earnings Per Share

 

Basic earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the reporting period. Diluted earnings per share (“diluted EPS”) is computed similarly to basic earnings per share, except that it includes the potential dilution that could occur if dilutive securities were exercised. Potentially dilutive securities include common shares related to stock options and non-vested stock awards (collectively “stock awards”). Stock awards are excluded from the calculation of diluted EPS in the event that they are subject to performance conditions or are antidilutive.

 

 

The following table presents a reconciliation of the denominators used in the computation of basic and diluted earnings per share (shares in thousands):

 

 

The following stock awards were excluded from the calculation of diluted EPS:

 

 

 

Note 9. Commitments and Contingencies

 

In February 2018, Dr. James L. Orrington II filed a purported civil class action in the United States District Court for the Northern District of Illinois, Eastern Division, alleging that we sent unsolicited advertisements to telephone facsimile machines.  The complaint includes counts alleging violations of the Telephone Consumer Protection Act (“TCPA”), the Illinois Consumer Fraud Act, Conversion, Nuisance, and Trespass to Chattels.  The plaintiff seeks monetary damages, injunctive relief, and attorneys’ fees.  Additionally, in June 2018, Rowan Family Dentistry, Inc. filed a purported class action complaint in the United States District Court for the District of Colorado making substantially the same claims as Dr. James L. Orrington II and seeking substantially the same relief. During the three months ended September 30, 2018, we recorded an expense of $3,300 as an estimate of our potential loss associated with the matter.  The expense is recorded in estimated legal settlement on our condensed consolidated statements of income and a corresponding liability is included in estimated legal liability on our condensed consolidated balance sheets. We intend to vigorously defend the aforementioned cases; however, we may ultimately be subject to liabilities greater or less than the amount accrued.

 

Note 10. Segment Information

 

We have four reporting segments: Sterilization and Disinfection Control, Instruments, Cold Chain Monitoring, and Cold Chain Packaging. The following tables set forth our segment information:

 

 

 

 

 

 

 

 

(1)

Reconciling items include selling, general and administrative, research and development, estimated legal settlement, and other (income) expenses

 

 

 

As of September 30, 2018, all long-lived assets are located in the United States except for $6,203, $6,667 and $15,585 which are associated with our French, Canadian, and German subsidiaries, respectively.

 

Revenues from external customers are attributed to individual countries based upon locations to which the product is shipped or exported, as follows:

 

 

No foreign country exceeds 10 percent of total revenues.

 

Note 11. Subsequent Event

 

In October 2018, we announced that our Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, payable on December 17, 2018, to shareholders of record at the close of business on November 30, 2018.

---

 

---

---

---

---

---

---

---

---

---